BioTissue Surgical Email Format
Biotechnology ResearchFlorida, United States11-50 Employees
BioTissue Surgical is a biotechnology research company based in Miami, Florida, that develops regenerative tissue therapies derived from human amniotic membrane and umbilical cord. With more than three decades of research, it has characterized and preserved the biology and functionality of AM and UC. The company is the sole provider of a matrix that combines both tissues, with the aim of delivering functional allografts for regenerative healing in adult wound environments. Based in Miami, the company operates with a small to mid-sized team and focuses on expanding regenerative healing solutions across medical disciplines. One notable development in its product line is CAM360 AmnioGraft, a shelf-stable cryopreserved amniotic membrane introduced in 2024. In January 2026, BioTissue announced an asset sale of its surgical and wound care business to BioStem Technologies, signaling a shift in its asset portfolio and broadening BioStem's wound care offerings.